BR112020012712A8 - Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc - Google Patents
Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do sncInfo
- Publication number
- BR112020012712A8 BR112020012712A8 BR112020012712A BR112020012712A BR112020012712A8 BR 112020012712 A8 BR112020012712 A8 BR 112020012712A8 BR 112020012712 A BR112020012712 A BR 112020012712A BR 112020012712 A BR112020012712 A BR 112020012712A BR 112020012712 A8 BR112020012712 A8 BR 112020012712A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- 101001041010 Conus radiatus Iota-conotoxin RXIA Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc. são fornecidos nesse relatório descritivo compostos de fórmula (i-i): e sais farmaceuticamente aceitáveis deste; em que p, r1, r3a, r2a, r11a, r11b, r6a e r6b são definidos nesse relatório descritivo. também são fornecidas nesse relatório descritivo composições farmacêuticas que compreendem um composto de fórmula (i-x) e métodos de utilização dos compostos, por exemplo, no tratamento de distúrbios relacionados ao snc.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610069P | 2017-12-22 | 2017-12-22 | |
US62/610,069 | 2017-12-22 | ||
US201762611983P | 2017-12-29 | 2017-12-29 | |
US62/611,983 | 2017-12-29 | ||
US201862620095P | 2018-01-22 | 2018-01-22 | |
US62/620,095 | 2018-01-22 | ||
US201862722781P | 2018-08-24 | 2018-08-24 | |
US62/722,781 | 2018-08-24 | ||
US201862734718P | 2018-09-21 | 2018-09-21 | |
US62/734,718 | 2018-09-21 | ||
PCT/US2018/067277 WO2019126741A1 (en) | 2017-12-22 | 2018-12-21 | Compositions and methods for treating cns disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112020012712A2 BR112020012712A2 (pt) | 2020-11-24 |
BR112020012712A8 true BR112020012712A8 (pt) | 2022-03-03 |
Family
ID=65234663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020012712A BR112020012712A8 (pt) | 2017-12-22 | 2018-12-21 | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210101928A1 (pt) |
EP (1) | EP3728284A1 (pt) |
JP (2) | JP7382326B2 (pt) |
KR (1) | KR20200104350A (pt) |
CN (2) | CN111770929B (pt) |
AU (2) | AU2018388408B2 (pt) |
BR (1) | BR112020012712A8 (pt) |
CA (1) | CA3086299A1 (pt) |
IL (2) | IL275562B1 (pt) |
MA (1) | MA51315A (pt) |
MX (3) | MX2020006599A (pt) |
WO (1) | WO2019126741A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2806877T (lt) | 2012-01-23 | 2019-12-10 | Sage Therapeutics Inc | Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
JP2021505608A (ja) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス, インコーポレイテッド | CNS障害を処置するためのジュウテリウム化された21−[4−シアノ−ピラゾール−1−イル]−19−ノル−プレガン−3.α−オール−20−オン誘導体 |
CN113166193A (zh) | 2018-10-12 | 2021-07-23 | 萨奇治疗股份有限公司 | 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇 |
BR112021024033A2 (pt) * | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
WO2021023213A1 (zh) * | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
IL296645A (en) | 2020-03-25 | 2022-11-01 | Sage Therapeutics Inc | Use of substances to treat respiratory conditions |
WO2021262836A1 (en) | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3087940A (en) * | 1959-02-03 | 1963-04-30 | Advance Growth Capital Corp | 19-methyl pregnene derivatives |
GB1036418A (en) * | 1962-07-09 | 1966-07-20 | Syntex Corp | 19-alkyl-steroids and process for their production |
DE2438020A1 (de) * | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
US9512170B2 (en) * | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
DK3488852T3 (da) | 2013-08-23 | 2021-02-01 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
ES2808855T3 (es) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
TW202235090A (zh) | 2014-10-16 | 2022-09-16 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
ES2935476T3 (es) * | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
EP3280420B1 (en) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
-
2018
- 2018-12-21 KR KR1020207021156A patent/KR20200104350A/ko not_active Application Discontinuation
- 2018-12-21 MA MA051315A patent/MA51315A/fr unknown
- 2018-12-21 AU AU2018388408A patent/AU2018388408B2/en active Active
- 2018-12-21 IL IL275562A patent/IL275562B1/en unknown
- 2018-12-21 CN CN201880089688.1A patent/CN111770929B/zh active Active
- 2018-12-21 EP EP18839991.9A patent/EP3728284A1/en active Pending
- 2018-12-21 CA CA3086299A patent/CA3086299A1/en active Pending
- 2018-12-21 JP JP2020534229A patent/JP7382326B2/ja active Active
- 2018-12-21 US US16/955,714 patent/US20210101928A1/en active Pending
- 2018-12-21 MX MX2020006599A patent/MX2020006599A/es unknown
- 2018-12-21 BR BR112020012712A patent/BR112020012712A8/pt unknown
- 2018-12-21 IL IL310454A patent/IL310454A/en unknown
- 2018-12-21 WO PCT/US2018/067277 patent/WO2019126741A1/en active Application Filing
- 2018-12-21 CN CN202311667677.6A patent/CN117946202A/zh active Pending
-
2020
- 2020-07-13 MX MX2023005098A patent/MX2023005098A/es unknown
- 2020-07-13 MX MX2023005099A patent/MX2023005099A/es unknown
-
2023
- 2023-06-07 JP JP2023093975A patent/JP2023113862A/ja active Pending
-
2024
- 2024-03-05 AU AU2024201459A patent/AU2024201459A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019126741A1 (en) | 2019-06-27 |
IL275562A (en) | 2020-08-31 |
IL310454A (en) | 2024-03-01 |
MX2023005098A (es) | 2023-05-24 |
AU2018388408B2 (en) | 2023-12-21 |
EP3728284A1 (en) | 2020-10-28 |
JP2023113862A (ja) | 2023-08-16 |
CN117946202A (zh) | 2024-04-30 |
BR112020012712A2 (pt) | 2020-11-24 |
AU2018388408A1 (en) | 2020-07-09 |
IL275562B1 (en) | 2024-03-01 |
MX2023005099A (es) | 2023-05-23 |
JP7382326B2 (ja) | 2023-11-16 |
MA51315A (fr) | 2020-10-28 |
CA3086299A1 (en) | 2019-06-27 |
CN111770929A (zh) | 2020-10-13 |
JP2021506890A (ja) | 2021-02-22 |
RU2020123943A (ru) | 2022-01-24 |
CN111770929B (zh) | 2023-12-26 |
US20210101928A1 (en) | 2021-04-08 |
TW201929864A (zh) | 2019-08-01 |
MX2020006599A (es) | 2020-11-06 |
AU2024201459A1 (en) | 2024-03-21 |
KR20200104350A (ko) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112020012712A8 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc | |
MX2022007915A (es) | Compuestos de benzopirazol y analogos de estos. | |
BR112018072570A2 (pt) | piperidinas como inibidores de menina | |
WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
WO2016011390A8 (en) | Irak4 inhibiting agents | |
SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
DK3805233T3 (da) | (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling | |
BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
BR112018005904A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
BR112018005870A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
BR112017028456A2 (pt) | composto, e, método de prevenção e/ou tratamento de hiv | |
SV2016005313A (es) | Derivados de carboxamida | |
BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
BR112016029065A2 (pt) | ?composto, composição farmacêutica, e, uso de um composto? | |
BR112018072887A2 (pt) | método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto | |
BR112017021669A2 (pt) | formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações | |
MX2017013049A (es) | Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022024203-0 PROTOCOLO 870220110031 EM 28/11/2022 12:40. |